Volume 36 Issue 6
Nov.  2020
Turn off MathJax
Article Contents
Article Navigation >  Journal of Nanjing University of traditional Chinese Medicine  > 2020  >  36(6): 820-825
DENGLai-jun, DONGYang, WANGCui, SUNWei-guo, ZHANZhao-min, SUNChang-gang. Clinical Study of Dahuang Zhechong Pill in the Treatment of JAK2-V617F Positive Polycythemia Vera[J]. Journal of Nanjing University of traditional Chinese Medicine, 2020, 36(6): 820-825.
Citation: DENGLai-jun, DONGYang, WANGCui, SUNWei-guo, ZHANZhao-min, SUNChang-gang. Clinical Study of Dahuang Zhechong Pill in the Treatment of JAK2-V617F Positive Polycythemia Vera[J]. Journal of Nanjing University of traditional Chinese Medicine, 2020, 36(6): 820-825.
shu

Clinical Study of Dahuang Zhechong Pill in the Treatment of JAK2-V617F Positive Polycythemia Vera

  • 1.

    Department of Hematology, Weifang Hospital of Traditional Chinese Medicine, Weifang, 261000, China

  • 2.

    Department of Clinical Medicine, Weifang Hospital of Traditional Chinese Medicine, Weifang, 261000, China

  • 3.

    Department of Hematology, Harbin Institute of Hematologic and Oncology, Harbin, 150000, China

  • Publish Date: 2020-11-10
    Abstract
  • OBJECTIVE To observe the clinical efficacy of Dahuang Zhechong Pill in the treatment of blood stasis syndrome due to JAK2-V617F positive polycythemia vera (PV) and its influence on the expression of tumor angiogenesis-related factors. METHODS A total of 43 patients were enrolled and randomly divided into 21 cases in the control group and 22 cases in the treatment group. Ten patients with immune thrombocytopenia served as blank controls. The control group received oral hydroxyurea， and the treatment group was treated with Dahuang Zhechong Pills on the basis of the control group. After 3 months of treatment， applying the myeloproliferative neoplasms symptom assessment form total symptom score (MPN-SAF-TSS) and blood-stasis syndrome score form to evaluate the clinical efficacy and adverse reactions of patients in the two groups， as well as compare the indexes before and after treatment， including the expression levels of bone marrow Williams tumor gene (WT1)， vascular endothelium growth factor (VEGF)， cyclooxygenase-2 (COX-2) and microvessel density (MVD). RESULTS After treatment， the MPN-SAF-TSS evaluation scores of the treatment group decreased after treatment (P<0.05，P<0.01)， fatigue， weight loss， abdominal discomfort， inattention， skin itching， and bone pain were significantly improved， which were better than the control group (P<0.05，P<0.01). After treatment， the symptoms of blood stasis， concretion， and signs of tongue proper in the two groups were improved significantly (P<0.05，P<0.01)， and the treatment group was better than the control group (P<0.05). The effective rates of the two groups were 77.3% and 61.9%， respectively， and the treatment group was better than the control group (P<0.05). There was no statistical difference in adverse reactions between the two groups (P>0.05). Compared with the blank group， the expressions of WT1， VEGF， COX-2， and MVD in the two groups were high before treatment (P<0.05)， but lowered after treatment (P<0.05，P<0.01). The decreased levels of WT1， VEGF， COX-2 in the treatment group were better than those of the control group (P<0.05). CONCLUSION Quyu Liangxue prescriptions are effective in treating PV， and it can inhibit WT1 gene expression and tumor angiogenesis. There is no obvious adverse reaction， which is worthy of further research and promotion.

     

    • FullText(HTML)
  • loading
    • References(22)
  • [1]
    ARBER D， ORAZI A， HASSERJIAN R， et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia[J].Blood，2016，127(20):2391-2405.
    [2]
    陈信义，麻柔，李冬云.规范常见血液病中医病名建议[J].中国中西医结合杂志，2009，29(11):1040-1041.
    [3]
    QUINTAS-CARDAMA A， KANTARJIAN H， MANSHOURI T， et al. Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera[J].J Clin Oncol，2009，27(32):5418-5424.
    [4]
    中国中西医结合学会活血化瘀专业委员会. 血瘀证中西医结合诊疗共识[J].中国中西医结合杂志，2011，31(6):839-844.
    [5]
    EMANUEL RM， DUECK AC， GEYER HL， et al. Myeloproliferative neoplasm(MPN) symptom assessment form total symptomscore: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPN[J].J Clin Oncol，2012，30(33):4098-5103.
    [6]
    沈悌，赵永强.血液病诊断及疗效标准[M].4版.北京:科学出版社，2018:72-73.
    [7]
    皋文君，刘砚燕，袁长蓉.国际肿瘤化疗药物不良反应评价系统-通用不良反应术语标准4.0版[J].肿瘤，2012，32(2):142-144.
    [8]
    中药新药临床研究指导原则[M].北京:中国医药科技出版社，2002:233-237.
    [9]
    付建珠，徐倩，赵亚玲，等.干扰素抑制JAK2V617F阳性骨髓增殖性肿瘤血管新生的机制[J].中华医学杂志，2015，95(46):3727-3732.
    [10]
    赵亚玲，张丽军，付建珠，等.IFN-α2b对JAK2V617F突变的骨髓增殖性肿瘤COX-2表达及血管新生的影响[J].四川大学学报(医学版)，2016，47(4):473-478.
    [11]
    张仲景.金匮要略[M].北京:中国中医药出版社，2005:45-46.
    [12]
    付莉霞，王颖韶，白洁.中国真性红细胞增多症研究现状[J].中国实用内科杂志，2019，39(2):127-131.
    [13]
    BAI J， SHAO Z， JING L， et al.Clinical analysis of 185 patients with polycythemia vera[J].Chin J Hematol，2002，23(11):578-580.
    [14]
    BAI J， XUE YP， YE L，et al.The risk factors for thrombosis， myelofibrosis and leukemia transformation in patients with polycythemia vera[J].Chin J Hematol， 2007， 28(10): 685-688.
    [15]
    WEINFELD A， SWOLIN B， WESTIN. Molecular analyi of the erythropoietin receptor system in patients with polycythemia vera[J].Br J Haemato，1994，52:134-139.
    [16]
    COTTIN L， RIOU J， BOYER F， et al. WT1 gene is overexpressed in myeloproliferative neoplasms， especially in myelofibrosis[J].Blood Cells Mol Dis，2019，75:35-40.
    [17]
    ABDEIAAL AA， ANFY RA， ZAHER AE， et al. Study of prognostic significance of marrow angiogenesis assessment in patients with de novo acute leukemia[J]. Hematology， 2015，20(9):504-510．
    [18]
    MOSCHETTA MG， MASCHIO LB， JARDIM-PERASSI BV，et al. Prognostic value of vascular endothelial growth factor and hypoxia-inducible factor 1α in canine malignant mammary tumors[J].Oncol Rep，2015，33(5):2345-2353．
    [19]
    YU H， LIU Z， ZHOU H， et al. JAK-STAT pathway modu-lates the roles of iNOS and COX-2 in the cytoprotection of early phase of hydrogen peroxide preconditioning against apoptosis induced by oxidative stress[J].Neurosci Lett，2012，529(2):166-171．
    [20]
    HUA KT， LEE WJ， YANG SF，et al. Vascular endothelial growth factor-C modulates proliferation and chemoresistance in acute myeloid leukemic cells through an endothelin-1-dependent induction of cyclooxygenase-2[J].Biochim Biophys Acta， 2014，1843(2):387-397．
    [21]
    TAMMELA T， ALITALO K. Yet another function for hepatocyte growthfactor[J].Blood，2006，107(9):3424-3425．
    [22]
    CAO R， BIORNDAHL MA， GALLEGO MI， et al. Hepatocytegrowth factor is a lymphangiog Enic factor with an indirect mechanism of action[J].Blood，2006，107(9):3531-3536．
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (480) PDF downloads(502) Cited by()
    Proportional views
    Related

    Copyright © Journal of Nanjing University of traditional Chinese Medicine

    Sponsored by：Nanjing University of traditional Chinese MedicineAddress：No.138 xianlin Avenue, Qixia District, Nanjing cityChina Pos：210023

    Tel：025-85811935Email：xb@njucm.edu.cn

    Supported by: Beijing Renhe Information Technology Co., Ltd.    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return